2.93  -0.05 (-1.68%)		08-26 00:00
Open: 2.98 High: 2.98 Volume: 258,592		Pre. Close: 2.98 Low: 2.9 Market Cap: 39(M)

Short term
Mid term
Targets	6-month :	13.43	1-year :	15.68
Resists	First :	11.5	Second :	13.43
Pivot price	11.12
Supports	First :	11.07	Second :	10.81
MAs	MA(5) :	11.5	MA(20) :	11.04
	MA(100) :	10.92	MA(250) :	10.5
MACD	MACD :	0.1	Signal :	0
%K %D	K(14,3) :	100	D(3) :	100
RSI	RSI(14): 77.5
52-week	High :	17.14	Low :	10

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CREC ] has closed below upper band by 15.7%. Bollinger Bands are 71% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	11.51 - 11.57	11.57 - 11.61
Low:	11.36 - 11.43	11.43 - 11.49
Close:	11.4 - 11.5	11.5 - 11.59

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.

Wed, 21 Feb 2024
Cerecor Inc (NASDAQ:CERC) Just Removed One Of Its Major Risk Factors - Insider Financial

Wed, 08 Sep 2021
Cerecor Rebrands to Avalo Therapeutics - BioBuzz

Thu, 26 Aug 2021
Cerecor changes name to Avalor Therapeutics with new Nasdaq ticker - Seeking Alpha

Wed, 03 Jun 2020
Cerecor Inc. (NASDAQ:CERC) Receives IND Approval From The FDA For CERC-002 In Treatment of Coronavirus ... - BP Journal

Fri, 13 Mar 2020
Cerecor Inc. Just Released Its Yearly Earnings: Here's What Analysts Think - Yahoo Movies UK

Mon, 14 Oct 2019
Cerecor Announces $43 Million Deal with AYTU BioScience to Sell Pediatric Portfolio and Advance Towards NDA - BioBuzz

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	20 (M)
Shares Float	15 (M)
Held by Insiders	0 (%)
Held by Institutions	90.6 (%)
Shares Short	0 (K)
Shares Short P.Month	4 (K)

EPS	0.34
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.32
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-0.3 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-89.5 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	33.82
PEG Ratio	0
Price to Book value	-35.94
Price to Sales	0
Price to Cash Flow	-432.37

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.